Advanced Search

Study Preview



Study Title and Description

Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Author Dore GJ., Conway B., Luo Y., Janczewska E., Knysz B., Liu Y., Streinu-Cercel A., Caruntu FA., Curescu M., Skoien R., Ghesquiere W., Mazur W., Soza A., Fuster F., Greenbloom S., Motoc A., Arama V., Shaw D., Tornai I., Sasadeusz J., Dalgard O., Sullivan D., Liu X., Kapoor M., Campbell A., Podsadecki T.
Country Kirby Institute, UNSW Australia, and St. Vincent's Hospital, Sydney, Australia. Electronic address: gdore@kirby.unsw.edu.au.
Year 2016
Numbers Pubmed ID: 26321288

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.